HUP0002680A2 - VLA-4 által közvetített leukocita adhéziót gátló benzilszármazékok - Google Patents
VLA-4 által közvetített leukocita adhéziót gátló benzilszármazékokInfo
- Publication number
- HUP0002680A2 HUP0002680A2 HU0002680A HUP0002680A HUP0002680A2 HU P0002680 A2 HUP0002680 A2 HU P0002680A2 HU 0002680 A HU0002680 A HU 0002680A HU P0002680 A HUP0002680 A HU P0002680A HU P0002680 A2 HUP0002680 A2 HU P0002680A2
- Authority
- HU
- Hungary
- Prior art keywords
- substituted
- aryl
- group
- atom
- alkyl
- Prior art date
Links
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 231100000516 lung damage Toxicity 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010038910 Retinitis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- -1 amino- Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 206010014599 encephalitis Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 201000004193 respiratory failure Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány tárgya (I) és (IA) általános képletű vegyületekgyógyászati szempontból elfogadható sóik, és ezeket tartalmazó gyó-gyászati készítmények. A képletekben R1 jelentése adott esetbenhelyettesített alkil-, aril-, cikloalkil-, heterogyűrűs- ésheteroarilcsoport; R2 és R3 a nitrogénatommal és a szénatommal,amelyhez az R3 helyettesítő kötődik, telített heterogyűrűs csoportotvagy telített helyettesített heterogyűrűs csoportot képeznek, R5jelentése -(CH2)n-aril- vagy -(CH2)n -heteroarilcsoport, ahol n egészszám, amelynek értéke 1-4; Q jelentése -C(X)7- általános képletűcsoport, ahol R7 jelentése hidrogénatom vagy alkilcsoport és Xjelentése oxigénatom vagy kénatom; és R6 jelentése amino-, alkoxi-,helyettesített alkoxi-, cikloalkoxi-, helyettesített cikloalkoxi-, -O-(N-szukcinimidil)-, -NH-adamantil-, O-koleszt-5-en-3-<-il-csoport, -NHOY általános képletű csoport, ahol Y jelentése hidrogénatom, alkil-,helyettesített alkil-, aril- vagy helyettesített arilcsoport, -NH(CH2)pCOOY, -OCH2NR9R10 és -NHSO2Z általános képletű csoport. Atalálmány szerinti vegyületek alkalmasak VLA-4 által közvetítettgyulladásos megbetegedések kezelésére erre szoruló betegben, előnyösenasztma, Alzheimer-kór, ateroszklerózis, AIDS által okozott demencia,diabétesz, gyulladásos bélmegbetegedések szklerózis multiplex,reumatoid artritisz, szövet transzplantáció, tumor áttét, meningitisz,enkefalitisz, stroke és más agyi traumák, nefritisz, retinitisz,atópiás dermatitisz, pszoriázis, miokardiális iszkémia és akut,leukocita által közvetített tüdőkárosodás, mint a felnőttkori légzésielégtelenség tünetegyüttesben előforduló tüdőkárosodások kezelésére. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90358597A | 1997-07-31 | 1997-07-31 | |
PCT/US1998/015327 WO1999006436A1 (en) | 1997-07-31 | 1998-07-31 | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0002680A2 true HUP0002680A2 (hu) | 2001-07-30 |
HUP0002680A3 HUP0002680A3 (en) | 2001-12-28 |
Family
ID=25417733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0002680A HUP0002680A3 (en) | 1997-07-31 | 1998-07-31 | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1001975A1 (hu) |
JP (1) | JP2001512138A (hu) |
KR (1) | KR20010022413A (hu) |
CN (1) | CN1265675A (hu) |
AU (1) | AU8585198A (hu) |
BR (1) | BR9811573A (hu) |
CA (1) | CA2291473A1 (hu) |
HU (1) | HUP0002680A3 (hu) |
IL (1) | IL133635A0 (hu) |
NO (1) | NO20000414L (hu) |
PL (1) | PL338510A1 (hu) |
WO (1) | WO1999006436A1 (hu) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
US6093696A (en) * | 1997-05-30 | 2000-07-25 | Celltech Therapeutics, Limited | Tyrosine derivatives |
GB2365338B (en) * | 1997-06-14 | 2002-04-03 | Enzacta R & D Ltd | Therapeutic systems |
AU8163398A (en) | 1997-06-23 | 1999-01-04 | Pharmacia & Upjohn Company | Inhibitors of alpha4beta1mediated cell adhesion |
US6362341B1 (en) | 1997-07-31 | 2002-03-26 | Athena Neurosciences, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6559127B1 (en) | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US7030114B1 (en) | 1997-07-31 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6423688B1 (en) | 1997-07-31 | 2002-07-23 | Athena Neurosciences, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
EP1056714B1 (en) | 1998-02-26 | 2004-08-11 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
CA2394431C (en) * | 1999-12-16 | 2015-06-30 | Jane Relton | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
CN1413210A (zh) | 1999-12-28 | 2003-04-23 | 辉瑞产品公司 | 用于治疗炎症、自身免疫性疾病和呼吸系统疾病的vla-4依赖性细胞结合的非肽基抑制剂 |
AU2001248553A1 (en) | 2000-04-17 | 2001-10-30 | Celltech R And D Limited | Enamine derivatives as cell adhesion molecules |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
US6740654B2 (en) | 2000-07-07 | 2004-05-25 | Celltech R & D Limited | Squaric acid derivatives |
JP2004505110A (ja) | 2000-08-02 | 2004-02-19 | セルテック アール アンド ディ リミテッド | 3位置換イソキノリン−1−イル誘導体 |
MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
JP2005022976A (ja) * | 2001-07-18 | 2005-01-27 | Ajinomoto Co Inc | カルボン酸誘導体 |
MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
US20050215605A1 (en) * | 2002-03-28 | 2005-09-29 | Page Patrick N | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor |
EP3527228A1 (en) * | 2003-01-24 | 2019-08-21 | Biogen MA Inc. | Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
EP1753421B1 (en) * | 2004-04-20 | 2012-08-01 | Amgen Inc. | Arylsulfonamides and uses as hydroxysteroid dehydrogenase |
PT1778637E (pt) * | 2004-06-29 | 2012-05-25 | Aventis Pharma Inc | Composição de ligação a fkbp e sua utilização farmacêutica |
WO2008103378A2 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
BRPI0911652A2 (pt) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
EP3466977B1 (en) | 2010-04-16 | 2022-01-05 | Biogen MA Inc. | Anti-vla-4 antibodies |
CN102675244B (zh) * | 2011-03-16 | 2016-03-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻嗪酰胺衍生物及其在制备神经退行性疾病防治药物的用途 |
US20170002077A1 (en) | 2014-03-13 | 2017-01-05 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4β7インテグリンの阻害のための化合物 |
CN112969687A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
EP3873897A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN112969700A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04154732A (ja) * | 1990-10-18 | 1992-05-27 | Nippon Kayaku Co Ltd | 光学分割法 |
AU693143B2 (en) * | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
-
1998
- 1998-07-31 IL IL13363598A patent/IL133635A0/xx unknown
- 1998-07-31 HU HU0002680A patent/HUP0002680A3/hu unknown
- 1998-07-31 BR BR9811573-1A patent/BR9811573A/pt not_active Application Discontinuation
- 1998-07-31 EP EP98937054A patent/EP1001975A1/en not_active Withdrawn
- 1998-07-31 JP JP2000505191A patent/JP2001512138A/ja not_active Withdrawn
- 1998-07-31 PL PL98338510A patent/PL338510A1/xx unknown
- 1998-07-31 AU AU85851/98A patent/AU8585198A/en not_active Abandoned
- 1998-07-31 WO PCT/US1998/015327 patent/WO1999006436A1/en not_active Application Discontinuation
- 1998-07-31 CN CN98807764A patent/CN1265675A/zh active Pending
- 1998-07-31 KR KR1020007000993A patent/KR20010022413A/ko not_active Application Discontinuation
- 1998-07-31 CA CA002291473A patent/CA2291473A1/en not_active Abandoned
-
2000
- 2000-01-27 NO NO20000414A patent/NO20000414L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0002680A3 (en) | 2001-12-28 |
KR20010022413A (ko) | 2001-03-15 |
PL338510A1 (en) | 2000-11-06 |
JP2001512138A (ja) | 2001-08-21 |
CA2291473A1 (en) | 1999-02-11 |
EP1001975A1 (en) | 2000-05-24 |
IL133635A0 (en) | 2001-04-30 |
NO20000414L (no) | 2000-03-28 |
CN1265675A (zh) | 2000-09-06 |
AU8585198A (en) | 1999-02-22 |
WO1999006436A1 (en) | 1999-02-11 |
NO20000414D0 (no) | 2000-01-27 |
BR9811573A (pt) | 2000-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0002680A2 (hu) | VLA-4 által közvetített leukocita adhéziót gátló benzilszármazékok | |
HUP0003921A2 (hu) | VLA-4 által közvetített leukocitaadhéziót gátló szulfonilezett dipeptidszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0002495A1 (hu) | VLA-4 Által közvetített leukocita adhéziót gátló dipeptidszármazékok és rokon vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NZ272015A (en) | Treatment of insufficiency of central choline functions using a cyclic amide (substituted 1,3-benzoxazin-2-one derivative) | |
MXPA01007335A (es) | Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4). | |
NO941211L (no) | Farmakologisk aktive pyrimidinforbindelser og fremgangsmåte for deres fremstilling | |
HUP9802859A2 (hu) | Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként | |
NZ508033A (en) | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | |
HUP9801711A2 (hu) | Helyettesített imidazolidin-2,4-dion-vegyületek felhasználása fájdalomcsillapító szerként alkalmazható gyógyszerkészítmények előállítására | |
DK0756595T3 (da) | Substituerede 1,3-oxathiolaner med antivirale egenskaber | |
EA200401562A1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ИНГИБИРУЮЩИЕ АДГЕЗИЮ ЛЕЙКОЦИТОВ, ОПОСРЕДОВАННУЮ α4 ИНТЕГРИНАМИ | |
NZ510955A (en) | Tricyclic nitrogen containing ring system useful as CRF receptor antagonists | |
ATE143943T1 (de) | Arylglycinamidderivate, verfahren zur deren herstellung und deren verwendung zur therapie der dysurie | |
ATE72431T1 (de) | 5-gliedrige heterocyclische angiotensinumwandlungsenzym-inhibitoren. | |
ATE85614T1 (de) | Psychotropische bizyklische imide. | |
HUP0000894A2 (hu) | Szubsztituált (1,3-bisz(ciklohexilmetil)-1,2,3,6-tetrahidro-2,6-dioxo-9H-purin-8-il)fenil-származékok és eljárás előállításukra | |
TR199902350T2 (xx) | Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler. | |
ATE64391T1 (de) | Azacyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutisches mittel. | |
HUP0201315A2 (hu) | 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények | |
HUP9801751A2 (hu) | Benzopiránszármazékok, azok előállítása és alkalmazása, valamint ilyen származékokat tartalmazó gyógyszerkészítmények | |
ATE56713T1 (de) | 1,2,3,4,4a,9b-hexahydro-4aaminoalkyldibenzofurane, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
NO20005932L (no) | Nye forbindelser avledet fra <alfa>-D-xylose, og deres fremstilling og terapeutiske bruk | |
EP0728748A4 (en) | NEW BENZODIAZEPINE DERIVATIVE | |
ES502073A0 (es) | Metodo de producir lactamas antihipertensoras | |
HUP0202607A2 (hu) | Görcsoldó és nyugtató hatású 4-amino-1-aril-1,5-dihidropirrol-2-on-származékok, eljárás az előállításukra és az azokat tartalmazó gyógyszerkészítmények |